Categories
Health

Doximity CEO ignored Silicon Valley knowledge, constructed $10 billion firm

Jeff Tangney, CEO, of Doximity at the New York Stock Exchange for their IPO, June 24, 2021.

Source: NYSE

Jeff Tangney launched his first health-tech start-up, Epocrates, in the middle of the dot-com bubble. While the company survived the crash and eventually went public, the endgame was a disappointing acquisition for less than $300 million.

By the time Tangney started his next venture, Doximity, in 2010, he’d learned a few things: Don’t raise too much money. Don’t burn too much cash. Fix a real problem for doctors.

With Doximity, Tangney created a web service that’s both a professional network — think LinkedIn for doctors — and a secure way for medical experts to communicate and share information with patients and colleagues. It now counts 1.8 million medical pros in the U.S. as users, including over 80% of physicians.

On Thursday, Doximity debuted on the New York Stock Exchange, closing the week with a market cap of almost $10 billion after raising around $500 million in its IPO. Tangney’s stake is worth $2.9 billion.

Those are big numbers especially when you consider that, prior to this week, Doximity never showed up on a “unicorn” list of billion-dollar tech companies. Its last financing round in 2014 valued the company at under $400 million. Tangney said that because Doximity is profitable it still hasn’t touched the $50 million it raised seven years ago.

“I did resist some of the Silicon Valley wisdom of, you need to go big, you need to hire 40 more salespeople and do all these things,” Tangney, 48, said in an interview on Thursday, after ringing the bell at the NYSE.

In Doximity’s target market, there’s no point in aiming for rocketship growth, Tangney said. The company generates revenue from drugmakers, who use the site to market treatments to a very targeted audience, and health systems looking to promote content to doctors across the country. It’s also a recruiting tool hospitals and health centers use to fill key jobs.

Tangney recognized early on that he could expand only as rapidly as customer budgets would allow.

“The reality of health care and our clients, who are very staid institutions, a lot of non-profits that have been around for 100 years, is that even if you lean in and hire tons of sales and marketing people, they’re not going to let you grow,” Tangney said.

He’s also not inclined to pay for branding just for the sake of building his profile — another reason why the company has remained largely unknown in Silicon Valley even though it’s headquartered in San Francisco. Doximity’s advertising budget for last fiscal year totaled $2.6 million, or roughly the amount Uber spends on an average day.

Tangney said the best advertising has come from doctors touting the product within their practitioner networks.

Meanwhile, the company generated over $200 million in revenue last fiscal year and produced over $50 million in net income.

Climbing trip at Stanford

Tangney’s journey to Doximity started in the late 1990s while he was living in New York with a trained physician named Richard Fiedotin. From their un-air-conditioned apartment, the pair came up with the idea of creating an app for the Palm Pilot, which had just hit the market, that would allow doctors to get critical information.

Tangney and Fiedotin took that idea with them to Stanford Graduate School of Business, where they met another physician named Tom Lee. The three bonded over the intersection of tech and health care while on a teambuilding climbing trip for students in the program.

In 1998, they started what became Epocrates, and over the next two years raised about $40 million from some of Silicon Valley’s top health investors. As mobile moved to BlackBerry devices and then to iPhones, Epocrates gained traction as a way for doctors to make decisions about prescriptions and patient safety while on the move.

The venture capitalists told Tangney to hire like crazy, so he did. Then came the tech crash and the crisis from the 9/11 terrorist attacks. In 2002, Epocrates was forced to cut a bunch of jobs, Tangney said.

The company held on, but it was a slog. Fiedotin left a few years later, and Lee departed to start One Medical, a chain of primary care clinics that uses technology to improve the patient experience. Tangney stuck around a bit longer, and tried to take Epocrates public. Then came the financial crisis of 2008, and the company had to withdraw its prospectus.

Tangney finally left in late 2009, a year before the eventual IPO and four years before Athenahealth bought the company for $293 million.

“There was a point during the last couple years of my tenure where it felt like we were in this tunnel, marching toward a goal,” Tangney said. “I wasn’t having as much fun. When you’re not in that place of loving what you do, you’re not doing your best work.”

Tangney had spent the past decade selling products to medical centers and talking to doctors about the challenges they faced doing their jobs. He kept those conversations going and learned that communication was a constant point of stress, whether it’s getting in touch with patients, other doctors, administrators or recruiters. In Tangney’s estimation, 80% of communication in the industry “is done via snail mail and fax.”

“Software is indeed eating the world but it kind of choked a little bit on health care,” he said.

Shari Buck had worked with Tangney at Epocrates. She’s one of the first people he approached with the idea of creating a professional network designed for doctors. Buck said she hopped on board “without reservation,” joining as one of the three co-founders, along with Nate Gross, a doctor who is also the founder of health-tech incubator Rock Health.

Doximity co-founders Jeff Tangney (left), Nate Gross and Shari Buck

Doximity

“Before we had an office, Jeff would drive up to Marin to meet me,” Buck said. “We would meet in a workspace above the garage. We used to laugh at how Apple it was,” she said, referring to the storied location where Steve Jobs and Steve Wozniak started their computer company.

Tangney also turned to Lee as a sounding board and advisor. At One Medical, Lee had the perfect test audience for Tangney: A growing base of doctors who were enthusiastic about technology.

At the time, Tangney was not at all focused on revenue, but was rather pursuing an approach more akin to consumer internet start-ups, trying to build a big base of engaged users with the hope that money would eventually follow.

Lee said they batted around ideas for future revenue opportunities. Helping medical recruiters find talent was a clear possibility.

“Recruiting doctors is not a well-defined profession and had been done poorly,” said Lee, who’s now founder and CEO of health company Galileo. “A doctor receives a lot of job opportunities. In classic medical marketing, you’d get these glossy photos of opportunities that were completely outdated, showing glorious pictures of suburban communities and symphony life and fishing.”

Best ideas come over cocktails

For Tangney, product development at Doximity has always been centered around what doctors need. So he created a medical advisory board a decade ago, bringing together a few dozen physicians in the network for a weekend every year.

The group gets together on a Saturday afternoon to provide feedback on new products, learn about updates that could be coming and for some general brainstorming. The talks continue informally over evening drinks and then resume Sunday morning, ending with lunch.

“Software is indeed eating the world but it kind of choked a little bit on health care.”

While Doximity had to skip this year’s gathering because of Covid-19, the event has been held in Napa and at Pebble Beach, and more recently at the company’s San Francisco office.

“It’s been probably the biggest influence on our product roadmap,” Buck said. “We talk about what we plan on building, individual features and new crazy ideas that we have. The best ideas come at cocktail hour on Saturday night.”

Buck said Tangney is known for carrying around little notebooks that he diligently fills up cover to cover over the two days.

Kevin Spain of Emergence Capital attended the Napa weekend in 2012, not long after his venture firm led Doximity’s first investment, a $10.8 million financing round.

Spain was thoroughly invested in Doximity’s success, and not just because of the money Emergence had on the line. He wasn’t yet a partner at the firm but had convinced his superiors to back a pre-revenue business. It was an atypical bet for Emergence, which focuses on early-stage cloud software companies.

Spain said that while board meetings were instructive because he could see signups going in the right direction and engagement on the site increasing, the Napa weekend was much more insightful. He got to hear directly from doctors about what they needed to improve their practice.

“They felt like they had a hand in co-creating this thing Doximity was building,” said Spain, whose firm owns a $1.35 billion stake in the company as of Friday’s close. “I’d never seen that before.”

Some of those doctors ultimately made good money from the IPO. Doximity allocated up to 3.5 million shares to doctors on the platform, representing 15% of the offering. After Doximity’s stock price jumped 115% in its first two days, the value of shares owned by doctors climbed from $91 million to over $195 million.

“Physicians are sort of outsiders in the financial markets and business world,” Tangney said. “Yet in our life and world they’re the insiders, they’re the people we care about most. We’d rather the shares go to them if there’s a pop than to some hedge fund somewhere.”

One challenge for Tangney as he continues to seek expansion opportunities is that there’s a finite universe of users and the core product already reaches the vast majority of them. The company serves more than 80% of U.S. physicians and over 90% of recent medical school graduates. There are only about 1 million doctors in the country.

Still, Tangney sees a decade of revenue growth ahead. There are digital ad dollars to capture as pharmaceutical companies move spending online. And there’s the power of medical referrals, helping doctors get patients to the right places based on where the top experts work and which hospital specializes in treating a particular disease.

Doximity also just entered telehealth, a $4.3 billion market opportunity, according to the prospectus. As a response to the pandemic, Doximity launched a video-based virtual visit service that doctors can use from their existing app and patients can use without having to download anything.

The company said it signed over 150 telehealth subscription agreements with medical systems and served over 63 million virtual visits in the fiscal year that ended in March. Yet the product only accounts for 2% of its revenue.

At the highest level, Tangney said, health care accounts for 18% of the U.S. economy, so there’s no shortage of money available if Doximity’s service continues to add valuable features.

“We’re steadfastly focused on these very busy million people who really take care of the sick all day and aren’t given great tools to collaborate with each other easily and to make care better,” he said.

WATCH: Disrupting Healthcare

Categories
Health

Ceremony Assist plummets; CEO Heyward Donigan cites Covid for cautious outlook

Rite Aid CEO Heyward Donigan told CNBC on Thursday she’s “cautiously optimistic” the U.S. would avoid another round of strict Covid restrictions despite the presence of the delta variant.

“We all hope that enough people get vaccinated that we don’t have the variant become so significant that our markets shut down again,” Donigan said on “Squawk Box.”

Even so, the chief executive said the drug store chain was being judicious with its financial projections due, in part, to how unpredictable the coronavirus pandemic’s impact on business has been.

Shares of Rite Aid sank roughly 14% on Thursday, sending the company’s stock market value under $1 billion, as Wall Street digested mixed first-quarter results and weaker earnings guidance.

Rite Aid’s forecast for adjusted EBITDA — earnings before interest, taxes, depreciation and amortization — came in at $440 million and $480 million in fiscal year 2022, below estimates of $524 million, according to FactSet.

“We’re being very cautious because we had a miss last quarter due to the complete meltdown, I’ll call it, of cough, cold, flu — both in the pharmacy and in the front end because there just was no cough, cold, flu,” Donigan said, alluding to the recent surprisingly calm flu season in the U.S. and its impact on Rite Aid.

“We just didn’t realize how far down, how evaporated that business would actually be. So as we look forward, we think we need to be very cautious and prudent in our guidance,” said Donigan, who has been CEO of Pennsylvania-based Rite Aid since August 2019.

“We are expecting some improvement. We’re not expecting full improvement,” Donigan added.

She also acknowledged, “It’s very hard, it remains very hard to predict, a full-year result in a retail pharmacy in the middle of a pandemic because we are … still in the throes of this to some degree.”

The company projected full-year revenue of between $25.1 billion and $25.5 billion, which exceeded Wall Street’s expectations of $24.66 billion, according to FactSet.

Rite Aid’s outlook is not factoring in potential Covid vaccine boosters or vaccinations for children under the age of 12, Donigan noted. Trials examining the vaccine in kids under age 12 are currently ongoing.

The Food and Drug Administration cleared Pfizer’s Covid vaccine for use in kids ages 12 to 15 a little more than a month ago. Moderna, which also makes a two-dose vaccine, has asked the FDA to expand its emergency use authorization to cover adolescents from 12 to 17.

Categories
Politics

Colonial Pipeline paid $5M ransom someday after hack, CEO tells Senate

Joseph Blount, JR., President and Chief Executive Officer, Colonial Pipeline is sworn in as he attends a hearing to examine threats to critical infrastructure, focusing on examining the Colonial Pipeline cyber attack at the U.S. Capitol in Washington, U.S., June 8, 2021.

Andrew Caballero-Reynolds | Reuters

WASHINGTON — Colonial Pipeline’s CEO told a Senate committee on Tuesday the company paid the $5 million ransom one day after Russian-based cybercriminals hacked its IT network, crippling fuel deliveries up and down the East Coast.

Joseph Blount Jr. told members of the Senate Homeland Security and Governmental Affairs Committee in prepared remarks that the company learned of the attack shortly before 5 a.m. on May 7, when an employee discovered a ransom note on a system in the IT network.

The note said hackers had “exfiltrated” material from the company’s shared internal drive, and it demanded approximately $5 million in exchange for the files.

The company was attacked by a ransomware program created by DarkSide, a cyber criminal group believed to operate out of Russia.

Blount said that shortly after discovering the ransom note, the employee notified a supervisor and the decision was made to immediately shut down the entire pipeline.

“At approximately 5:55 A.M. employees began the shutdown process,” Blount wrote. “By 6:10 A.M., they confirmed that all 5,500 miles of pipelines had been shut down.”

The decision to shut down the entire pipeline was driven by “the imperative to isolate and contain the attack to help ensure the malware did not spread to the Operational Technology network, which controls our pipeline operations, if it had not already.”

The shutdown caused major disruptions to gas delivery up and down the East Coast, as trucks struggled to restock gas stations, and long lines developed at pumps, especially in the Southeast. Airline operations also were disrupted.

Blount’s testimony revealed just how quickly the company decided to suspend operations, and it provided new details about the first few days after the attack.

The company believes attackers “exploited a legacy virtual private network profile that was not intended to be in use,” Blount told senators.

But he admitted that the account was not protected by multifactor authentication, which is currently the company standard in most of its operations. Blount said the password was complicated, though. “It was not a ‘Colonial 123’-type password.”

Blount also testified about the approximately $5 million in ransom that the company paid to the DarkSide hackers. He revealed that Colonial Pipeline paid the ransom one day after the attack.

“I made the decision that Colonial Pipeline would pay the ransom to have every tool available to us to swiftly get the pipeline back up and running,” Blount said in his opening statement. “It was one of the toughest decisions I have had to make in my life.”

“At the time, I kept this information close hold because we were concerned about operational security and minimizing publicity for the threat actor,” he said.

In response to a question about whether the company paid ransom to an entity under U.S. sanctions, Blount said the company checked the sanctions list maintained by the Office of Foreign Asset Control before making the payment.

The day before Blount testified, U.S. law enforcement officials announced that they were able to recover $2.3 million in bitcoin from the hacker group.

Blount also told senators that the company contacted the FBI within hours of discovering the attack.

This story will be updated throughout the Senate hearing.

Categories
Health

Biogen CEO says $56,000 yearly for Alzheimer’s drug is ‘honest,’ guarantees to not hike value for at the very least four years

Michel Vounatsos, CEO of Biogen, told CNBC Monday that the list price of $ 56,000 per year for the company’s FDA-approved Alzheimer’s drug aducanumab was “fair”.

However, the Massachusetts-based biotech has vowed not to increase the price of the drug, which it marketed under the Aduhelm name, for the next four years, Vounatsos said.

The price of the drug reflects “two decades without innovation” and will also allow Biogen to continue investing in its pipeline of drugs for other diseases, he said in an interview with CNBC’s “Power Lunch”. He added that the company works closely with the federal health insurance program Medicare, as well as with private insurers.

Biogen’s shares rose up to 60% on Monday after the Food and Drug Administration announced it approved the company’s drug for the disease. It’s the first drug approved by U.S. regulators to slow cognitive decline in people with Alzheimer’s, and the first new drug for the disease in nearly two decades.

Alzheimer’s disease is a progressive neurodegenerative disease that slowly destroys memory and thinking skills. The Alzheimer’s Association estimates that more than 6 million Americans live with it. According to the group, this number is expected to rise to almost 13 million by 2050.

The FDA’s decision was eagerly awaited. The drug is also expected to generate billions in revenue for the company offers new hope to friends and families of patients living with the disease.

Biogen said Monday that aducanumab’s list price is $ 56,000 a year, which was higher than the $ 10,000-25,000 price some analysts had expected. The expenses for the patient depend on their health insurance.

When asked if the company expects patient pressures on price to drop, Vounatsos found that the disease and other forms of dementia cost the US over $ 600 billion annually and patients $ 500,000 annually.

It is time to “invest” in treatment, he added.

Categories
Health

Amazon health-care menace? Teladoc CEO says it is ‘overrated’

The Amazon Pharmacy home screen on a smartphone arranged in the Brooklyn Borough of New York, U.S., on Tuesday, Nov. 17, 2020.

Gabby Jones | Bloomberg | Getty Images

Ask a sports star before a game whether their team is going to win and they’re likely to say yes with confidence. And then cue the headlines that will sensationalize the hubris. But would you expect an athlete to say — would you want them to think — they’re about to lose?

The heads of companies sometimes talk about the competition in a similar way, and they shouldn’t be in the CEO hot seat without confidence in their company’s ability to win.

Take Teladoc Health CEO Jason Gorevic, recently asked at the CNBC Healthy Returns Summit about the threat Amazon poses in health care.

“Based on the fact that it has one enterprise client of 385 employees, it is overrated,” Gorevic said, answering a question about Amazon Care, the retail and tech giant’s app-based primary care entry in Teladoc’s market, which signed up its first client, Peloton-owned fitness equipment company Precor, in May.

Should the Teladoc CEO be more worried? Even after Amazon’s deal with Berkshire Hathaway and J.P. Morgan to take on the status quo with its health care joint effort, Haven, fell apart, the merchandising giant still has a big market to exploit.

Amazon Care is expected to expand to its own employees in all 50 states this summer. It has been adding workers faster than any company in history, more than 500,000 in 2020. It also has had a deal with employer health provider Crossover Health for in-person employee health clinics that continues to expand across states with a goal of putting these clinics within a few miles of all Amazon employees, especially in light of the attention its workplace injury rates have received.

J.P. Morgan is moving on and deeper into health care after Haven, recently announcing it will move ahead with its own effort to invest in new health-care ideas, to be offered among its 165,000 employees and families.

Virtual health here to stay

As society has moved rapidly from the awareness phase of virtual care to the expectation phase, those expectations have increased, and Teladoc has added services like mental health treatment as part of what Gorevic tells CNBC is the future “unified experience” with patients.

“Virtual care is not a stay at home phenomenon,” Gorevic said. “The utilization we are seeing across multiple conditions all indicate it is here to stay.”

He cited first quarter 2021 results during which visit volume was up 69% year over year in spite of the fact that seasonal flu-related visits were down 90%.

Nevertheless, Teladoc shares have cratered, down from a peak earlier this year above $290 to roughly half that level, ending trading last week slightly above $146. But Gorevic says investors are missing the bigger picture, and overlooking improving numbers. The biggest quarterly number he cites: revenue per member, per month, which in Q1 2021 was $2.25, versus 87 cents a year ago.

Others cite the rapid M&A taking place in Teladoc’s market as reason to worry.

Walmart acquired MeMD in May; two other telemedicine competitors, Doctor on Demand and Grand Rounds, recently merged.

“Everyone feels like they have to have a press release that says something about telehealth to be relevant,” Gorevic told CNBC Healthy Returns. “I’m not surprised by any of these moves.”

“This pandemic has thrown the whole market into motion. As we looked at the market, we said we needed to be bold, and we see where it’s going,” the Teladoc CEO said, citing its $18 billion acquisition of chronic disease management company Livongo, which is focused on diabetes, and its expanding mental health services.

Gorevic says health-care consumers are overwhelmed by health-care websites and apps and want a unified experience, and the company is seeing that in multi-product bookings, which in 2020 represented two-thirds of bookings.

Amazon and the fear of disruption

Amazon’s ability to upend, or at least send waves of terror, through the health care industry has already been seen in the launch of its online pharmacy, which led to shares of Goodrx dropping from over $52 to roughly $33 after the announcement last October.

Wall Street analysts who cover Teladoc see Amazon’s presence as significant, yet not all agree it is an acute threat to Teladoc currently.

“Leery of Amazon’s initiatives here,” wrote Sean Wieland, managing director and a senior research analyst focusing on health-care information technology and health-care services at Piper Sandler, in response to an email.

“Even Amazon would have to get the enterprise market on board one employer at a time, as it’s a highly fragmented market and that would take years. Also, it’s a significant lift to go from offering urgent care visits on demand to whole person health care.”

More from CNBC’s Healthy Returns

Charles Rhyee, managing director and senior research analyst covering health-care technology and distribution at Cowen & Co., said Goodrx is a good example of how Amazon can disrupt health care, and it would be a mistake to ignore Amazon’s potential. But he thinks the threat in pharmacy is more direct than in telehealth.

“It’s is a mature market. There are tons of pharmacies out there and it is not a growth sector. In the truest sense, more of zero sum game,” Rhyee said, and that is something Amazon can afford to win at the expense of CVS or Goodrx.

Telehealth visits still a fraction of the market

Telehealth is still a nascent field and that may play to Teladoc’s favor in the years ahead.

“We are all talking about it because of Covid forcing everyone to seek virtual care, but if you think about how many visits Teladoc will do this year, it’s 12 million to 13 million visits,” Rhyee said.

That compares to a U.S. market in which there are one billion visits or more, annually, including mental health care.

Whether a Teladoc or American Well is growing in the telemedicine market, Rhyee says that amounts to about 2% to 3% of visits, a small fraction of what can be virtualized and an indicator that the market is going to expand.

“I’m not concerned,” Rhyee said. “Where Teladoc sits is not what Amazon is doing. It’s not just basic video visits to speak to a doctor for a minor thing. It is increasingly in multiple specialities and second opinions and Livongo. You can argue right now very few, if any, have that broad capabilities, and that’s why Doctor on Demand is merging with Grand Rounds.”

He looks at Amazon in basic care and pharmacy in a similar way to his analysis of Walmart’s health care after its acquisition of MeMD. “They want to provide some basic connectivity and prescriptions that can be dispensed at Walmart.”  

Why Teladoc shares have been volatile

Stocks move up and down in discrete periods of time, and that doesn’t always correspond to the longer-term trend. That’s part of the challenge for investors with Teladoc right now, trying to figure out what its growth looks like post-Covid.

Membership growth guidance for this year may not be as strong as some investors wanted coming out of Covid, and app tracking firms have shown slowing momentum in daily usage. Yet people using Teladoc less now than April of last year does not mean they are using it less than they were in 2019. And last year was unusual.

“We don’t know what virtual will look like in the end,” Rhyee said. 

The Cowen analyst has a $240 price target on the stock and says at $140 it is trading at roughly 8 times forward revenue, which is up from where it traded before Covid, but that was when “people didn’t believe it was a real business.”

Rhyee says he will worry more about Amazon if it starts stringing together acquisitions in health care, including in the chronic condition management space. “That would tell me they are much more serious about it,” he said.

As long as Amazon Care is one enterprise client and its own employees, the Teladoc outlook will be based elsewhere.

The idea of competition between Teladoc and Amazon may be missing the real threat Amazon poses in health care, according to David Grossman, research manager director at Stifel. That includes disrupting the legacy providers in insurance and pharmacy benefits managers.

Teladoc is disrupting traditional providers by creating a virtual 24/7 network on demand that can offer a potentially lower-cost alternative. Those traditional providers now forced to offer telemedicine are more of a near-term threat to Teladoc, in Grossman’s view, as they evolve from starting telehealth “literally overnight” to incorporating virtual care as a permanent feature of their care delivery models.

“Virtual care is now table stakes for providers, while 15 months ago it was barely on the radar screen,” he said.

Setting up appointments online and having telehealth as an option may be one of the features Amazon offers, but that is a shortsighted way to view what Amazon is after in the health care system.

Amazon is saying we take over everything. It’s not lets go after Teladoc. That’s incidental.

David Gross, Stifel analyst

Grossman, who is concerned about Teladoc’s ability to grow revenue and margins, says Gorevic is a smart guy building a reasonable model. Now they can pitch health plans on using a provider network they have created at lower cost for employers, if employees agree to access services virtually as a first stop. That disintermediates the traditional provider network, but he does not see Amazon stopping there or even thinking in those terms specifically.

“Amazon is saying we take over everything,” Grossman said, looking at traditional health care market that is flawed in delivery and pricing and adds little value. “It’s not lets go after Teladoc. That’s incidental.”

Taking cost out of the system is what Amazon already has proven to be great at, squeezing out players that don’t offer value and shouldn’t be there. “I’m rooting for them in that sense,” the Stifel analyst said.

But whether it is Amazon’s or Walmart’s efforts that are emerging in health care, the models to watch do not exclude Teladoc. “There is no indication we should write it off,” Grossman said.

Teladoc shares are down for a lot of reasons, starting with the market rotation out of growth names and the market acknowledging that traditional providers are ramping up their own telemedicine products.

“Everyone points to Amazon, and let’s be fair, it was a high multiple stock and the market is getting out of the stay at home trade and pricing how high can utilization translate into pricing” Grossman said. He added that Teladoc has struggled to convince the street of its pricing power. “They have been opaque.”

The company is growing monthly revenue per member, as Gorevic noted, but the Stifel analyst was quick to point out the recent Q1 growth relied on the acquisition of Livongo. Livongo is the largest provider of virtual chronic care and that is top of mind for employers, but Teladoc has a lot of work left to do to prove demand for it is a secular driver of its business growth.

Behavioral health, meanwhile, is the fastest- growing incremental service but there is only so much that can be delivered on an automated basis, so it becomes a staffing platform to match supply and demand and help sole mental health practice proprietors fill their book of business like an Uber or Lyft.

While the 8 times revenue the company is trading at might seem less than rich, double-digit revenue multiple companies tend to be in sectors like software, where scalability comes fast and at high margins. Teladoc’s subscription-heavy sales model means a majority of revenue is fixed while the costs remain variable.

“Their claim all along has been as utilization goes up it’s good for them, but there is no pricing algorithm around that. We don’t know how to calculate that,” Grossman said.

Companies like Teladoc and American Well can grow members, and grow utilization among members, but how either of those growth measures factor into pricing power remains unpredictable. Utilization can go up, but revenue not match it. And that contributes to investor concerns about its scalability.

“It is factually correct they can get more per member with more services and there are lots of opportunities, but lots of competition for each module and booking,” Grossman said. The company’s scale and visibility give it an advantage, “but lots remains uncertain,” he said.

Gorevic told CNBC this is not a pandemic story. “Something else is going on here. People are reaching out for other things.”

Mental health, dermatology, and chronic conditions including diabetes, and health issues linked to it such as weight loss. “Not one and done things, and that’s why I am convinced,” the Teladoc CEO said.

Building the virtual primary care model and convincing payers and employers that it is most cost-effective to choose this option, and agree to have members enter the health system virtually as the first step, is the bigger opportunity to drive higher revenue per member, Grossman said, and longer-term it is the more sustainable way to disrupt the traditional provider network.

In that sense, Teladoc is taking market share just like Amazon would, and they can grow for a longer period of time. That may be a discrete disruption in health care that becomes permanent. The biggest disruption in health care, though, is not about telemedicine.

“All roads lead into the payers,” Grossman said. “That’s where the level of satisfaction is low and the control they have is high.”

Stay connected with Healthy Returns

For a front row seat at CNBC Events, you can hear directly from the visionary executives, innovators, leaders and influencers taking the stage in “The Keynote Podcast.” Listen now, however you get your podcasts.

For more exclusive insights from our reporters and speakers, sign up for our Healthy Returns newsletter to get the latest delivered straight to your inbox weekly.

Categories
Business

Tesla faces strain as EV competitors heats up, ex-Ford CEO says

Elon Musk brought electric vehicles into the mainstream with Tesla. Now the EV company is grappling with the consequences of its own innovation, former Ford Motor CEO Mark Fields told CNBC on Wednesday.

“One of the many things he did is he pushed the industry toward taking EV seriously,” Fields said of Musk, the chief executive of Tesla. “He has real competition now, and that’s why you’re seeing some of their share in some of the major markets under a lot of pressure.”

Tesla shares fell for the third-straight session against the backdrop of multiple challenging headlines for the car manufacturer. One, in particular, is that the San Carlos, California-based company lost some of its grip on the electric vehicle market in April.

Fields was critical of Tesla’s reliance on selling carbon credits to supplement its profits, suggesting it’s a harbinger of more challenges.

“When you look at their year-to-date earnings and their earnings last year, they made a heck of a lot more in selling CO2 credits than they did their total company profit and net profit,” Fields said. “As those credits dry up, there’s going to be a lot of pressure to make money and better margins on their vehicles.”

According to Credit Suisse analyst Dan Levy, Tesla’s global market share was 11% in April, down from 29% in March. He noted share losses in the China, Europe and U.S. markets.

Fields attributed the shift in EV market share to traditional auto giants, such as General Motors and Ford, making headway in the space as new products are announced and come online.

He highlighted that Volkswagen is now leading in EVs in Europe and the Ford Mach E is taking share in the U.S. Ford, which Fields led between 2014 and 2017, in May revealed its electric F-150 to much fanfare.

After soaring in 2020, Tesla shares have dropped more than 14% so far in 2021. The stock, which trades more like a tech stock, closed 3% lower Wednesday at $605.12 a share.

Shares of traditional car companies, taking the form of cyclical stocks, are up double digits this year and have outgained the market through Wednesday.

Ford shares have put up some of the biggest gains, rallying almost 69% this year to $14.91 at the close Wednesday.

Categories
Business

Mondelez CEO calls $2 billion Chipita acquisition a win for each corporations

Dirk Van de Put, CEO of Mondelez, described the latest acquisition on Thursday as a “win win” for both companies involved in the deal.

The oreo maker announced on Wednesday that it had acquired Chipita, a Greek company whose croissants and baked snacks contributed to sales of $ 580 million last year. The purchase will give Mondelez back approximately $ 2 billion, which will be funded through new debt issuance and existing cash on hand.

“We can use their sales and presence to build our sales, but also to bring our brands to their products,” Van de Put told CNBC’s Jim Cramer about Mad Money. “Imagine a Cadbury chocolate or Milka chocolate croissant.”

Van De Put said that while Chipita’s products are mostly popular in Eastern Europe, they have growth potential around the world, particularly in emerging markets.

“I think it’s a real win-win,” he said.

Mondelez’s shares are up 8% this year for a market value of $ 89.2 billion.

Categories
Business

Snowflake CEO urges buyers to be affected person with inventory throughout cloud transition

Snowflake CEO Frank Slootman said Wednesday that shareholders need to be patient with the company’s stock because the cloud transition is not happening overnight.

“Our business is really going to conduct itself really over considerable, long periods of time,” Slootman said in an interview with CNBC’s Jim Cramer on “Mad Money.” “That’s sort of the message to investors to really understand we’re signing on here for a journey that’s five to 10 years.”

The comments came as shares of Snowflake tumbled as much as 8% in extended trading after the company reported fiscal first-quarter results.

While revenue grew 110% year over year to a better-than-expected $228.9 million, the data-analytics software firm also reported a net loss of $203.2 million. That’s up from $93.6 million in the same period a year earlier. At the same time, Snowflake also raised its full-year guidance for product revenue.

Snowflake went public in September in a record-breaking IPO, with shares closing that initial trading day at $253.93. However, the stock was below that level at Wednesday’s close. Snowflake shares are also down 16% year to date, as investors have rotated out of high-flying growth names into economically sensitive companies that stand to benefit from the Covid recovery.

Despite the recent moves on Wall Street, Slootman stressed that the company’s software is only becoming more important as enterprises shift away from databases tied to hardware.

“These are big, big changes that we are experiencing in the marketplace, and we’re just super happy to be in the middle of that and be an enabler of that,” he said, adding that Snowflake places its focus on growing at scale. “We’re not a growth-at-all-costs company.”

Categories
Health

Jury can hear restricted proof of CEO way of life

Theranos founder Elizabeth Holmes leaves the Robert F. Peckham Federal Building with her defense team in downtown San Jose, Calif., on Tuesday, May 4, 2021.

MediaNews Group/The Mercury News via Getty Images | MediaNews Group | Getty Images

Jurors in the trial of Elizabeth Holmes will hear evidence about her extravagant lifestyle as Theranos CEO but with some limitations.

That’s the ruling issued by U.S. District Court Judge Edward Davila late Saturday as part of a 100 page response to motions in Holmes’ upcoming criminal trial.

The judge granted in part Holmes’ motion to exclude evidence referencing her extravagant lifestyle outside of her position as chief executive of the blood-testing start-up.

“The Government may introduce evidence that Holmes enjoyed a lifestyle as Theranos CEO that is comparable to those of other tech company CEOs. This includes salary, travel, celebrity, and other perks and benefits commensurate with the position,” Davila wrote in the filing.

However, “references to specific purchases or details reflecting branding of clothing, hotels, or other personal items is not relevant, and the prejudicial effect of that evidence outweighs any probative value,” the judge added.

The ruling is a partial victory for Holmes as prosecutors cannot introduce details about Holmes’ specific purchases and personal items outside of her position as CEO. Holmes lived in an expensive rental home, traveled by private jet, stayed at luxury hotels and employed Theranos-paid assistants to run her lavish shopping sprees.

“Each time Holmes made an extravagant purchase, it is reasonable to infer that she knew her fraudulent activity allowed her to pay for those items,” Davila wrote. “While the benefits of these purchases are not as directly tied to the fraud…it may still be probative of Holmes’ scienter.”

The ruling comes two weeks after Holmes battled it out with prosecutors in court over whether details of her wealth, lifestyle and perks she attained as CEO would be relevant to jurors in her trial.

At the height of Theranos, the start-up was valued at $9 billion and Holmes was touted as the world’s youngest self-made woman billionaire. The company collapsed in 2018 following a Wall Street Journal investigation that revealed failings in the blood-testing technology.

Davila ruled on more than 20 dueling motions on what jurors can hear in her trial, scheduled to begin on Aug. 30.

A motion by the government to admit business-related text messages between Holmes and her co-defendant Ramesh “Sunny” Balwani was denied by Davila.

Prosecutors say the messages show the two top executives knew how much trouble Theranos was in before it collapsed. In a November 2014 text to Holmes, Balwani describes one Theranos lab as a “f*cking disaster zone,” adding he would “work on fixing this.”

Holmes and Balwani have both pled not guilty to a dozen criminal wire fraud charges in connection with deceiving investors, patients and doctors.

Categories
Business

Barrick Gold CEO pans cryptocurrencies as an inferior retailer of worth than gold

Barrick Gold CEO Mark Bristow on Thursday rejected the idea that cryptocurrencies are a better store of value than traditional gold.

Bitcoin bulls have argued that the limited supply of digital coins and the noticeable growth make them a better hedge against inflation than gold.

Bristow, who starred in CNBC’s “Mad Money”, pushed back this characterization and criticized speculative assets as too volatile to be considered a safe investment.

“The one thing you can’t do is that nobody can print gold,” he told Jim Cramer. “We can still make cryptocurrencies.”

The supply of Bitcoin, which like gold but must be mined digitally, is limited to 21 million. According to the blockchain explorer service Blockchain for cryptocurrencies, there are currently more than 19 million coins in the simulation.

In terms of gold, approximately 244,000 tons of metal have been mined to date based on a census conducted by the United States Geological Survey. According to Bristow, gold is still a rarity.

“As a mining company, gold miners have not been able to replace the reserves they have mined since the turn of the century,” he said. “We only replaced 50% of the gold that we mined.”

Barrick Gold is a $ 44 billion miner.

The comments come after a major collapse in speculative cryptocurrency markets last week, specifically a 30% drop in Bitcoin to nearly $ 30,000. The digital currency has since bounced back along with other crypto names and is trading near $ 40,000. Bitcoin was under $ 10,000 a year ago.

Meanwhile, the price of gold is up 3% last week and 5% last year.

Barrick’s shares rose nearly 1% to $ 24.81 on Thursday. The stock is up 9% since the start of the year.